-
Je něco špatně v tomto záznamu ?
18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?
TW. Georgi, R. Kluge, L. Kurch, L. Chavdarova, D. Hasenclever, D. Stoevesandt, T. Pelz, J. Landman-Parker, WH. Wallace, J. Karlen, A. Fernández-Teijeiro, M. Cepelova, A. Fosså, W. Balwierz, A. Attarbaschi, RA. Ammann, J. Pears, A. Hraskova, A....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1964 do Před 1 rokem
Open Access Digital Library
od 1964-01-01 do Před 6 měsíci
Medline Complete (EBSCOhost)
od 1960-01-01
- MeSH
- dítě MeSH
- fluorodeoxyglukosa F18 * MeSH
- Hodgkinova nemoc farmakoterapie patologie MeSH
- indukční chemoterapie * MeSH
- lidé MeSH
- mladiství MeSH
- nádory kostí diagnostické zobrazování sekundární MeSH
- nádory kostní dřeně diagnostické zobrazování sekundární MeSH
- pozitronová emisní tomografie * MeSH
- retrospektivní studie MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
To determine whether the current 18F-FDG PET response criterion for skeletal involvement in Hodgkin lymphoma (HL) is suitable, we performed a systematic evaluation of the different types of skeletal involvement and their response on PET after 2 cycles of chemotherapy (PET-2). A secondary objective was to observe the influence of the initial uptake intensity (measured as qPET) and initial metabolic tumor volume (MTV) of skeletal lesions on the PET-2 response. Methods: The initial PET scans of 1,068 pediatric HL patients from the EuroNet-PHL-C1 trial were evaluated for skeletal involvement by central review. Three types of skeletal lesions were distinguished: PET-only lesions (those detected on PET only), bone marrow (BM) lesions (as confirmed by MRI or BM biopsy), and bone lesions. qPET and MTV were calculated for each skeletal lesion. All PET-2 scans were assessed for residual tumor activity. The rates of complete metabolic response for skeletal and nodal involvement on PET-2 were compared. Results: Of the 1,068 patients, 139 (13%) showed skeletal involvement (44 PET-only, 32 BM, and 63 bone). Of the 139 patients with skeletal involvement, 101 (73%) became PET-2-negative in the skeleton and 94 (68%) became PET-2-negative in the lymph nodes. The highest number of PET-2-negative scans in the skeleton was 42 (95%) in the 44 PET-only patients, followed by 22 skeletal lesions (69%) in the 32 BM patients and 37 (59%) in the 63 bone patients. Lesions that became PET-2-negative showed a lower initial median qPET (2.74) and MTV (2 cm3) than lesions that remained PET-2-positive (3.84 and 7 cm3, respectively). Conclusion: In this study with pediatric HL patients, the complete response rate for skeletal involvement on PET-2 was similar to that for nodal involvement. Bone flare seemed to be irrelevant. Overall, the current skeletal PET response criterion-comparison with the local skeletal background-is well suited. The initial qPET and MTV of skeletal lesions were predictive of the PET-2 result. Higher values for both parameters were associated with a worse PET-2 response.
Department of Medical Oncology and Radiotherapy Oslo University Hospital Oslo Norway
Department of Nuclear Medicine National Hospital for Active Treatment in Oncology Sofia Bulgaria
Department of Nuclear Medicine University of Leipzig Leipzig Germany
Department of Pediatric Oncology Justus Liebig University Giessen Germany
Department of Pediatrics Inselspital Bern University Hospital Bern Switzerland
Department of Radiology University of Halle Halle Germany
Department of Radiotherapy University of Halle Halle Germany
Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands
Hôpital Armand Trousseau Paris France
Institute for Medical Informatics Statistics and Epidemiology University of Leipzig Leipzig Germany
Institute of Pediatrics Jagiellonian University Medical College Krakow Poland
Karolinska University Hospital Astrid Lindgrens Childrens Hospital Stockholm Sweden
Our Lady's Children's Hospital Dublin Ireland
Pediatric Oncology Unit Hospitales Universitarios Virgen Macarena y Virgen del Rocio Sevilla Spain
Service d'Hématologie Pédiatrique Hôpital Robert Debré Paris France
University Children's Hospital Bratislava Slovakia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035302
- 003
- CZ-PrNML
- 005
- 20191015100700.0
- 007
- ta
- 008
- 191007s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2967/jnumed.117.205633 $2 doi
- 035 __
- $a (PubMed)29653979
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Georgi, Thomas W $u Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany thomas.georgi@medizin.uni-leipzig.de.
- 245 10
- $a 18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required? / $c TW. Georgi, R. Kluge, L. Kurch, L. Chavdarova, D. Hasenclever, D. Stoevesandt, T. Pelz, J. Landman-Parker, WH. Wallace, J. Karlen, A. Fernández-Teijeiro, M. Cepelova, A. Fosså, W. Balwierz, A. Attarbaschi, RA. Ammann, J. Pears, A. Hraskova, A. Uyttebroeck, A. Beishuizen, K. Dieckmann, T. Leblanc, S. Daw, J. Baumann, D. Körholz, O. Sabri, C. Mauz-Körholz,
- 520 9_
- $a To determine whether the current 18F-FDG PET response criterion for skeletal involvement in Hodgkin lymphoma (HL) is suitable, we performed a systematic evaluation of the different types of skeletal involvement and their response on PET after 2 cycles of chemotherapy (PET-2). A secondary objective was to observe the influence of the initial uptake intensity (measured as qPET) and initial metabolic tumor volume (MTV) of skeletal lesions on the PET-2 response. Methods: The initial PET scans of 1,068 pediatric HL patients from the EuroNet-PHL-C1 trial were evaluated for skeletal involvement by central review. Three types of skeletal lesions were distinguished: PET-only lesions (those detected on PET only), bone marrow (BM) lesions (as confirmed by MRI or BM biopsy), and bone lesions. qPET and MTV were calculated for each skeletal lesion. All PET-2 scans were assessed for residual tumor activity. The rates of complete metabolic response for skeletal and nodal involvement on PET-2 were compared. Results: Of the 1,068 patients, 139 (13%) showed skeletal involvement (44 PET-only, 32 BM, and 63 bone). Of the 139 patients with skeletal involvement, 101 (73%) became PET-2-negative in the skeleton and 94 (68%) became PET-2-negative in the lymph nodes. The highest number of PET-2-negative scans in the skeleton was 42 (95%) in the 44 PET-only patients, followed by 22 skeletal lesions (69%) in the 32 BM patients and 37 (59%) in the 63 bone patients. Lesions that became PET-2-negative showed a lower initial median qPET (2.74) and MTV (2 cm3) than lesions that remained PET-2-positive (3.84 and 7 cm3, respectively). Conclusion: In this study with pediatric HL patients, the complete response rate for skeletal involvement on PET-2 was similar to that for nodal involvement. Bone flare seemed to be irrelevant. Overall, the current skeletal PET response criterion-comparison with the local skeletal background-is well suited. The initial qPET and MTV of skeletal lesions were predictive of the PET-2 result. Higher values for both parameters were associated with a worse PET-2 response.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a nádory kostní dřeně $x diagnostické zobrazování $x sekundární $7 D019046
- 650 _2
- $a nádory kostí $x diagnostické zobrazování $x sekundární $7 D001859
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a fluorodeoxyglukosa F18 $7 D019788
- 650 _2
- $a Hodgkinova nemoc $x farmakoterapie $x patologie $7 D006689
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a indukční chemoterapie $7 D060828
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a pozitronová emisní tomografie $7 D049268
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kluge, Regine $u Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
- 700 1_
- $a Kurch, Lars $u Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
- 700 1_
- $a Chavdarova, Lidia $u Department of Nuclear Medicine, National Hospital for Active Treatment in Oncology, Sofia, Bulgaria.
- 700 1_
- $a Hasenclever, Dirk $u Institute for Medical Informatics, Statistics, and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.
- 700 1_
- $a Stoevesandt, Dietrich $u Department of Radiology, University of Halle, Halle (Saale) Germany.
- 700 1_
- $a Pelz, Tanja $u Department of Radiotherapy, University of Halle, Halle (Saale), Germany.
- 700 1_
- $a Landman-Parker, Judith $u Hôpital Armand-Trousseau (Hôpitaux Universitaires Est Parisien), Paris, France.
- 700 1_
- $a Wallace, W Hamish $u Department of Paediatric Oncology, Royal Hospital for Sick Children, University of Edinburgh, Edinburgh, United Kingdom.
- 700 1_
- $a Karlen, Jonas $u Karolinska University Hospital, Astrid Lindgrens Childrens Hospital, Stockholm, Sweden.
- 700 1_
- $a Fernández-Teijeiro, Ana $u Pediatric Oncology Unit, Hospitales Universitarios Virgen Macarena y Virgen del Rocio, Sevilla, Spain.
- 700 1_
- $a Cepelova, Michaela $u Department of Pediatric Hematology and Oncology, University Hospital Motol and Second Medical Faculty of Charles University, Prague, Czech Republic.
- 700 1_
- $a Fosså, Alexander $u Department of Medical Oncology and Radiotherapy, Oslo University Hospital, Oslo, Norway.
- 700 1_
- $a Balwierz, Walentyna $u Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.
- 700 1_
- $a Attarbaschi, Andishe $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Ammann, Roland A $u Department of Pediatrics, Inselspital, Bern University Hospital, Bern, Switzerland.
- 700 1_
- $a Pears, Jane $u Our Lady's Children's Hospital, Dublin, Ireland.
- 700 1_
- $a Hraskova, Andrea $u University Children's Hospital, Bratislava, Slovakia.
- 700 1_
- $a Uyttebroeck, Anne $u University Hospitals of Leuven, Leuven, Belgium.
- 700 1_
- $a Beishuizen, Auke $u Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
- 700 1_
- $a Dieckmann, Karin $u Universitätsklinik für Strahlentherapie und Strahlenbiologie, Medizinische Universität Wien, Wien, Austria.
- 700 1_
- $a Leblanc, Thierry $u Service d'Hématologie Pédiatrique, Hôpital Robert-Debré, Paris, France.
- 700 1_
- $a Daw, Stephen $u University College London Hospitals, London, United Kingdom; and.
- 700 1_
- $a Baumann, Julia $u Department of Pediatric Oncology, Justus-Liebig-University, Giessen, Germany.
- 700 1_
- $a Körholz, Dieter $u Department of Pediatric Oncology, Justus-Liebig-University, Giessen, Germany.
- 700 1_
- $a Sabri, Osama $u Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
- 700 1_
- $a Mauz-Körholz, Christine $u Department of Pediatric Oncology, Justus-Liebig-University, Giessen, Germany.
- 773 0_
- $w MED00010072 $t Journal of nuclear medicine : official publication, Society of Nuclear Medicine $x 1535-5667 $g Roč. 59, č. 10 (2018), s. 1524-1530
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29653979 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191015101125 $b ABA008
- 999 __
- $a ok $b bmc $g 1451962 $s 1073852
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 59 $c 10 $d 1524-1530 $e 20180413 $i 1535-5667 $m The Journal of nuclear medicine $n J Nucl Med $x MED00010072
- LZP __
- $a Pubmed-20191007
